🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2023-504135-40-00
Completed Phase III

A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)

2023-504135-40-00 · tracked via the Priya Life Science EU tracker
Sponsor
Travere Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Nutritional and Metabolic Diseases
Decision date
27/04/2026
Enrollment target
22
Sites
Belgium, Ireland, Spain, Italy, Germany, France, Portugal, Poland

Condition studied

Classical Homocystinuria

Investigational medicinal product(s)

0.9 % sodium chloride saline solution (NaCL)Pegtibatinase

Eligibility

Age group
0-17 years, 65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

The change from baseline averaged over Week -3, Week -1, and Day 1 pre-dose in plasma tHcy levels averaged over Weeks 6 through 12 (6, 8, 10, and 12) in participants receiving standard of care and treated with pegtibatinase as compared to placebo

Endpoint detail

The change from baseline in plasma tHcy levels averaged post Week 12 (Weeks 16, 20, and 24) in participants receiving standard of care and treated with pegtibatinase as compared to placebo, The change from baseline in plasma Met levels averaged over Weeks 6 through 12 in participants receiving standard of care and treated with pegtibatinase as compared to placebo, The change from baseline in plasma Met levels averaged post Week 12 in participants receiving standard of care and treated with pegtibatinase as compared to placebo, The proportion of participants achieving tHcy <100 µM averaged over Weeks 6 through 12, among participants with tHcy ≥100 µM at baseline, The proportion of participants achieving tHcy <100 µM averaged post Week 12 among participants with tHcy ≥100 µM at baseline, The proportion of participants with tHcy <50 µM averaged over Weeks 6 through 12, The proportion of participants with tHcy <50 µM averaged post Week 12, The proportion of participants achieving tHcy reduction ≥35% from baseline averaged over Weeks 6 through 12, and averaged post Week 12, The proportion of participants achieving tHcy <100 µM and a ≥35% reduction from baseline averaged over Weeks 6 through 12, and averaged post Week 12 among participants with tHcy ≥100 µM at baseline, The proportion of participants with tHcy ≤15 µM averaged over Weeks 6 through 12, and averaged post Week 12

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2023-504135-40-00 on CTIS ↗ ← All trials in the EU